Дискуссионный клуб по нефрологии «Современный взгляд на терапию вторичного гиперпаратиреоза у пациентов на гемодиализе»


DOI: https://dx.doi.org/10.18565/nephrology.2021.4.72-76

5 ноября 2021 г. при поддержке компании «Амджен» состоялась прямая интернет-трансляция дискуссионного клуба по нефрологии «Современный взгляд на терапию вторичного гиперпаратиреоза у пациентов на гемодиализе».
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int 200; 64(3):1022-1026 2017 ;7(1):1–59.

  2. Block G.A., Kilpatrick R.D., Lowe K.A. et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 2013;8(12):2132–40. Doi:10.2215/CJN.04260413.

  3. Floege J., Kim J., Ireland E. et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26:1948–55.

  4. Chertow G.M., Block G.A., Correa-Rotter R. et al . Effect of cinacalcet on car-. diovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482–94.

  5. Chertow G.M., Block G.A., Correa-Rotter R. et al . Effect of cinacalcet on car-. diovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482–94.(Suppl 1-54).

  6. Schmidt I.M. et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study .Clinical Kidney Journal 2019, 12(5): 663–72.

  7. Ghimire S et al. Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLOS ONE 2015. DOI:10.1371/journal.pone.01441195.

  8. Tentori F., Wang M., Bieber B.A. et al. Recent changes in therapeuticapproaches and association with outcomes among patients withsecondary hyperparathyroidism on chronic hemodialysis: the DOPPSstudy. Clin J Am Soc Nephrol 2015; 10: 98–109.

  9. Karaboyas А. et al., Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease–Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients, AJKD 2021, Doi:10.1053/j.ajkd.2021.05.020.

  10. Neri L., Martini A., Andreucci V.E., Gallieni M., Rey L.A., Brancaccio D. MigliorDialisi Study Group. Regimen complexity and prescription adherence in dialysis patients. Am J Nephrol. 2011;34(1):71–6. Doi: 10.1159/000328391. Epub 2011 Jun 14. PMID: 21677429.

  11. Arenas M.D., Rodelo-Haad C., Pendon-Ruiz de Mier M.V., Rodriguez M. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent oral calcimimetics. Clin. Kidney J. 2020. Doi:10.1093/ckj/sfaa005.

  12. Campillejo R., et al. Effectiveness and safety of etelcalcetide in the long term in clinical practice in hemodialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_3, June 2020, gfaa142.P1426.

  13. Yokoyama K. et al. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan. Clinical and Experimental Nephrology 2020, doi: 10.1007/s10157-020-01936-2.

  14. 14. Bushinsky D.A., Chertow G.M., Cheng S., et al. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2019:1–10. Doi: 10.1093/ndt/gfz039

  15. Сunningham J. et al. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Reports 2019, 4:987–94.

  16. Block G.A., Bushinsky D.A., Cheng S., et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156–64.

  17. Nduka C., et al. ASN KidneyWeek 2021; Poster Abstract: PO0547

  18. Dörr K., Kammer M., Reindl-Schwaighofer R., Lorenz M., Prikoszovich T., Marculescu R., Beitzke D., Wielandner A., Erben R.G., Oberbauer R. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. Circ Res. 2021 May 28;128(11):1616–25.

  19. Adapted from Isakova T et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79,:1370–78.

  20. Makoto Kuro-o, Klotho and calciprotein particles as therapeutic targets against accelerated ageing. Clin Sci (Lond). 2021 Aug;135(15): 915–27.

  21. Cristian Rodelo-Haad, et al. FGF23, Biomarker or Target? Toxins (Basel). 2019 Mar; 1(3):175.

  22. Jair Munoz Mendoza, et al. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int. 2017 Mar; 91(3): 711–19.

  23. Mehta R, et al. Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. Clin J Am Soc Nephrol. 2017;12:1795–803.

  24. Evangelos Memmos, et al. Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis. BMC Nephrol. 2019; 20: 217.

  25. QiFeng Liu, et al. Correlation Between Soluble Klotho and Vascular Calcification in Chronic Kidney Disease: A Meta-Analysis and Systematic Review. Front Physiol. 2021;12:711904.

  26. Moe S.M. et al. Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015 Jun;26(6):1466–75.

  27. Behets G.J. et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int. 2015 Apr;87(4):846–56.

  28. Raggi P. et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011 Apr;26(4):1327–39.

  29. Xipell M. et al. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. Blood Purif. 2019;48(2):106–14.

  30. Itano Y. et al. A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial). Kidney Int Rep. 2020 Sep 18;5(12):2168–77.

  31. Palmer S.C. et al.. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis. 2020 Sep;76(3):321-330.

К содержанию номера

Бионика Медиа